Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2014

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Fentanyl citrate (Breakyl®) has been rejected for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. The manufacturer failed to make a submission.

Saxagliptin / Metformin (Kombogylze®) has been accepted for use in the treatment of type 2 diabetes mellitus in adults as triple oral therapy (in combination with a sulphonylurea) to improve glycaemic control when dual therapy (with metformin and a sulphonylurea), in combination with diet and exercise, does not provide adequate glycaemic control.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2014' on Email Share 'SMC Update - January 2014' on Delicious Share 'SMC Update - January 2014' on Digg Share 'SMC Update - January 2014' on Facebook Share 'SMC Update - January 2014' on reddit Share 'SMC Update - January 2014' on StumbleUpon Share 'SMC Update - January 2014' on Twitter

atomic-wealth

No Comments to “SMC Update - January 2014”

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer